V P Papastefanou, V M L Cohen. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Adenoma/diagnostic imagingAdenoma/pathologyAdenoma/radiotherapyAgedAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal, Humanized/therapeutic useBevacizumabBrachytherapyCiliary BodyCombined Modality TherapyEpitheliumHumansIris Diseases/drug therapyMaleNeovascularization, Pathologic/drug therapyRuthenium Radioisotopes/therapeutic useUltrasonographyUveal Neoplasms/diagnostic imagingUveal Neoplasms/pathologyUveal Neoplasms/radiotherapyVascular Endothelial Growth Factor A/antagonists & inhibitors
Substances: See more » Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedRuthenium RadioisotopesVEGFA protein, humanVascular Endothelial Growth Factor ABevacizumab
Year: 2012 PMID: 22814808 PMCID: PMC3470055 DOI: 10.1038/eye.2012.145
Source DB: PubMed Journal: Eye (Lond) ISSN: 0950-222X Impact factor: 3.775